CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that abstracts for the luspatercept and sotatercept phase 2 clinical trials were both selected for oral presentations in the Best of Clinical Trials sessions at the 13th International Symposium on Myelodysplastic Syndromes (MDS) being held April 29th - May 2nd in Washington, D.C. Acceleron and Celgene Corporation are jointly developing luspatercept and sotatercept.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
